Irinotecan, Topotecan
7,037 views
Oncology Pharm
- Bleomycin
- Dactinomycin, Actinomycin D
- Doxorubicin, Daunorubicin
- Azathioprine, 6-MP
- Cladribine
- Cytarabine
- Busulfan
- Cyclophosphamide, Ifosfamide
- Nitrosoureas
- Paclitaxel
- Vincristine, Vinblastine
- Cisplatin, Carboplatin, Oxaliplatin
- Etoposide, Teniposide
- Irinotecan, Topotecan
- Bevacizumab
- Erlotinib
- Cetuximab, Panitumumab
- Imatinib, Dasatinib
- Rituximab
- Bortezomib, Carfilzomib
- Trastuzumab
- Dabrafenib, Vemurafenib
- Raloxifene and Tamoxifen
- Hydroxyurea
- Procarbazine
Summary
Irinotecan and topotecan are both are DNA topoisomerase I inhibitors. By preventing DNA replication, they can be used to treat rapidly dividing cancer cells. Irinotecan has been shown to be effective in the treatment of colon cancer, and topotecan has been shown to be effective in the treatment of ovarian and small cell lung cancers. Side effects of these medications can include severe myelosuppression and diarrhea.
Key Points
- Irinotecan, Topotecan
- Mechanism
- Inhibit DNA topoisomerase I
- Prevents DNA unwinding and replication
- Inhibit DNA topoisomerase I
- Clinical use
- Colon cancer (irinotecan)
- Ovarian and small cell lung cancer (topotecan)
- Adverse effects
- Severe myelosuppression
- Diarrhea
- Mechanism